NOT.MU NOVARTIS N
- Market cap
- -
- P/E
- -
- P/B
- 8.20x
- ROE
- 27.3%
- Dividend yield
- 4.88%
- Fundamental score
- 2.9/5
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NOT.MU undervalued?
Graham numberThe Graham number of NOVARTIS N cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NOVARTIS N fundamental analysis
13 of 22 checks passedROE 2/2
High return on equity (27.3%), above 20%.
ROA 1/1
Return on assets (8.7%) is above the industry median (3.2%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (21.2%) is above the 5-year average (15.4% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (21.2%) is above the industry median (6.0%).
Revenue Growth 1/2
Revenue grew 9.3% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (98.6%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 8.4x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (8.2x) is above the industry median (1.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield cannot be calculated.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 10 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 55.9%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
NOVARTIS N stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
NOVARTIS N financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NOVARTIS N annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 49.4B | 50.1B | 53.2B | 48.7B | 49.9B | 44.0B | 43.5B | 46.7B | 51.7B | 56.7B | 58.0B |
| Gross Profit | 31.9B | 33.0B | 34.8B | 34.3B | 34.8B | 32.2B | 31.9B | 34.2B | 38.9B | 43.0B | 43.6B |
| Operating Income | 8.27B | 8.63B | 8.17B | 9.09B | 10.2B | 10.1B | 7.95B | 9.77B | 14.5B | 17.6B | 14.4B |
| EBITDA | - | 15.9B | 21.7B | 15.6B | 17.2B | 33.1B | 14.7B | 18.3B | 20.7B | 22.8B | 22.5B |
| Net Income | 6.71B | 7.70B | 12.6B | 11.7B | 8.07B | 24.0B | 6.96B | 14.9B | 11.9B | 14.0B | 10.2B |
| EPS | - | 3.32 | 5.46 | 5.18 | 3.58 | 11 | 3.28 | 7.27 | 6.05 | 7.33 | 5.38 |
| Balance Sheet | |||||||||||
| Total Assets | 130B | 133B | 146B | 118B | 128B | 132B | 117B | 99.9B | 102B | 111B | 117B |
| Total Liabilities | 55.2B | 58.9B | 66.9B | 62.8B | 71.1B | 64.0B | 58.0B | 53.2B | 58.1B | 64.4B | 79.6B |
| Shareholders' Equity | 74.8B | 74.2B | 78.6B | 55.5B | 56.6B | 67.7B | 59.3B | 46.7B | 44.0B | 46.1B | 37.2B |
| Cash & Short-term Investments | 7.01B | 8.86B | 13.3B | 11.1B | 9.66B | 12.4B | 7.52B | 13.4B | 11.5B | 11.4B | 8.87B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.5B | 12.6B | 14.3B | 13.6B | 13.7B | 15.1B | 14.2B | 14.5B | 17.6B | 19.1B | 20.1B |
| Capital Expenditure | 2.88B | 2.75B | 3.36B | 2.26B | 2.59B | 2.97B | 2.67B | 2.75B | 3.81B | 3.90B | 3.08B |
| Free Cash Flow | - | 9.88B | 10.9B | 11.4B | 11.1B | 12.1B | 11.6B | 11.7B | 13.8B | 15.2B | 17.0B |
| Ratios | |||||||||||
| ROE | 9.0% | 10.4% | 16.0% | 21.1% | 14.3% | 35.5% | 11.7% | 31.8% | 27.1% | 30.3% | 27.3% |
| ROA | 5.2% | 5.8% | 8.7% | 9.9% | 6.3% | 18.2% | 5.9% | 14.9% | 11.7% | 12.6% | 8.7% |
| Net Profit Margin | 13.6% | 15.4% | 23.7% | 24.1% | 16.2% | 54.6% | 16.0% | 31.8% | 23.1% | 24.7% | 17.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NOVARTIS N dividends
- Dividend yield
- 4.88%
- Forward dividend
- -
- Payout ratio
- 55.9%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 7.82B | 4.10 | 55.9% |
| 2024 | USD 7.62B | 3.86 | 63.8% |
| 2023 | USD 7.26B | 3.55 | 48.9% |
| 2022 | USD 7.51B | 3.54 | 107.9% |
| 2021 | USD 7.37B | 3.30 | 30.7% |
| 2020 | USD 6.99B | 3.10 | 86.6% |
| 2019 | USD 6.65B | 2.93 | 56.6% |
| 2018 | USD 6.97B | 3.01 | 55.2% |
| 2017 | USD 6.50B | 2.80 | 84.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 6:5 on Oct 4, 2023.
Who owns NOVARTIS N
Ownership data of NOVARTIS N is not available yet.
NOVARTIS N company profile
- Company name
- NOVARTIS N
- Ticker
- NOT.MU
- Exchange
- Munich Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- December
- Address
- Website
- -
About NOVARTIS N
There is no Profile data available for NOT.MU.